eCite Digital Repository

Differential multiple sclerosis treatment allocation between Australia and New Zealand associated with clinical outcomes but not mood or quality of life

Citation

Phyo, AZZ and Jelinek, GA and Brown, CR and O'Kearney, E and Neate, SL and De Livera, AM and Taylor, KL and Bevens, W and Simpson Jr, S and Weiland, TJ, Differential multiple sclerosis treatment allocation between Australia and New Zealand associated with clinical outcomes but not mood or quality of life, Multiple Sclerosis and Related Disorders, 30 pp. 25-32. ISSN 2211-0348 (2019) [Refereed Article]


Preview
PDF
564Kb
  

Copyright Statement

Copyright 2019 The Authors. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/

DOI: doi:10.1016/j.msard.2019.01.037

Abstract

Background: Differential treatment allocation may impact on clinical phenotype in MS and in turn upon quality of life (QoL).

Objectives: (a) Investigate the association between disease-modifying drugs (DMDs) use and relapse frequency, disability, clinically significant fatigue, and physical and mental health-related QoL among participants with MS residing in Australia and New Zealand (NZ); (b) assess whether these associations differed between Australia and NZ.

Methods: Disability and fatigue were measured by PDDS and FSS, respectively. QoL was assessed by MSQOL-54. Associations were assessed by binomial and multinomial logistic regression, as appropriate. Multivariable models were adjusted for demographic and clinical covariates, as appropriate.

Results: 837 participants (627 from Australia; 210 from NZ) were identified from an online cohort of people with MS. First- and second-generation DMD use was associated with higher adjusted-odds of fatigue and disability, though not with 12-month relapse number. DMD use was not independently associated with physical or mental QoL. The association of first-generation DMD use with moderate disability differed between nations, such that treatment was associated with lower odds in Australia but not in NZ; a similar but a small difference was found for severe disability. No differences were seen in the DMD association with relapse number, nor with fatigue or QoL, between Australia and NZ.

Conclusion:The differential treatment allocation associations in NZ are evident in the DMD-disability association, but there is no evidence that this treatment regimen has negative associations with fatigue, mood, or QoL.

Item Details

Item Type:Refereed Article
Keywords:disability, disease modifying drug, fatigue, multiple sclerosis, quality of life, relapse
Research Division:Medical and Health Sciences
Research Group:Neurosciences
Research Field:Central Nervous System
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Nervous System and Disorders
UTAS Author:Simpson Jr, S (Dr Steve Simpson JR)
ID Code:132995
Year Published:2019
Deposited By:Menzies Institute for Medical Research
Deposited On:2019-05-30
Last Modified:2019-07-31
Downloads:1 View Download Statistics

Repository Staff Only: item control page